RxDoctor Payments Data

Thomas Wilson, MD

Interventional Cardiology · Rapid City, SDNPI 1730503657

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (46.8%), travel and lodging and grants — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by Abbott at 26.9% of the total.

$18,385in general payments, 2019–2025

Across 177 payments — averaging $103.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$5K
  • Boston Scientific$4K
  • Medtronic$3K
  • Edwards Lifesciences$2K
  • Abiomed$1K
  • Cardiovascular Systems Inc.$635
  • plus $3K from 22 others

What the payments were for

  • Grants$1,1056%
  • Travel & lodging$8,33445%
  • Food & beverage$8,59747%
  • Education$3482%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few interventional cardiology providers in South Dakotato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$31,120
Medicare patients
294
Services billed
509

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban53$53,486
XareltoRivaroxaban29$22,718
BrilintaTicagrelor18$12,343
Metoprolol Succinate66$1,241
ClopidogrelClopidogrel Bisulfate27$413
Atorvastatin Calcium23$357
Losartan Potassium21$311
Rosuvastatin Calcium28$303
Carvedilol21$269
Isosorbide Mononitrate ErIsosorbide Mononitrate16$241
Furosemide31$239
Metoprolol Tartrate16$207
Spironolactone11$136

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$458$22,71829 claims
AstraZenecaBrilinta$118$12,34318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few interventional cardiology providers in South Dakotaon file to place this against a meaningful peer group, so we don't.

Other interventional cardiology in Rapid City

See the full list for South Dakota

Where these figures come from

Is this you, or does something look wrong? →